Iconovo AB (publ) (ICO.ST)
SEK 1.41
(7.25%)
SEK 1.41
(7.25%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -10.75 Million SEK | -214.9% |
| 2022 | -3.41 Million SEK | 96.4% |
| 2021 | -94.93 Million SEK | -53.9% |
| 2020 | -61.68 Million SEK | 30.81% |
| 2019 | -89.15 Million SEK | -68.06% |
| 2018 | -53.05 Million SEK | -136.03% |
| 2017 | -22.47 Million SEK | -135.62% |
| 2016 | -9.53 Million SEK | -86.2% |
| 2015 | -5.12 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -5.63 Million SEK | 95.03% |
| 2024 Q1 | -29.49 Million SEK | -174.23% |
| 2024 Q2 | -18.34 Million SEK | 37.81% |
| 2023 FY | -10.75 Million SEK | -214.9% |
| 2023 Q3 | -8.41 Million SEK | 55.82% |
| 2023 Q2 | -19.03 Million SEK | 45.97% |
| 2023 Q4 | -10.75 Million SEK | -27.89% |
| 2023 Q1 | -35.23 Million SEK | -931.53% |
| 2022 Q2 | -46.58 Million SEK | 34.81% |
| 2022 Q4 | -3.41 Million SEK | 89.17% |
| 2022 FY | -3.41 Million SEK | 96.4% |
| 2022 Q1 | -71.46 Million SEK | 24.72% |
| 2022 Q3 | -31.53 Million SEK | 32.3% |
| 2021 Q1 | -53.16 Million SEK | 13.81% |
| 2021 FY | -94.93 Million SEK | -53.9% |
| 2021 Q4 | -94.93 Million SEK | 11.27% |
| 2021 Q3 | -106.99 Million SEK | -131.31% |
| 2021 Q2 | -46.25 Million SEK | 13.0% |
| 2020 Q4 | -61.68 Million SEK | 14.42% |
| 2020 FY | -61.68 Million SEK | 30.81% |
| 2020 Q1 | -85.42 Million SEK | 4.19% |
| 2020 Q2 | -75.72 Million SEK | 11.35% |
| 2020 Q3 | -72.08 Million SEK | 4.81% |
| 2019 Q1 | -50.24 Million SEK | 5.29% |
| 2019 Q4 | -89.15 Million SEK | -118.78% |
| 2019 Q3 | -40.75 Million SEK | 10.75% |
| 2019 FY | -89.15 Million SEK | -68.06% |
| 2019 Q2 | -45.65 Million SEK | 9.12% |
| 2018 Q3 | -59.15 Million SEK | -3.98% |
| 2018 FY | -53.05 Million SEK | -136.03% |
| 2018 Q1 | -24.54 Million SEK | -9.22% |
| 2018 Q2 | -56.88 Million SEK | -131.72% |
| 2018 Q4 | -53.05 Million SEK | 10.31% |
| 2017 FY | -22.47 Million SEK | -135.62% |
| 2017 Q4 | -22.47 Million SEK | 0.0% |
| 2017 Q1 | 11.53 Million SEK | 0.0% |
| 2016 FY | -9.53 Million SEK | -86.2% |
| 2015 FY | -5.12 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 69.401% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 100.877% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 100.877% |
| Arcoma AB | -1.12 Million SEK | -853.487% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 109.788% |
| BICO Group AB (publ) | 927.9 Million SEK | 101.159% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 108.35% |
| CellaVision AB (publ) | -56.94 Million SEK | 81.112% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | 27.705% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -27.204% |
| C-Rad AB (publ) | -127.6 Million SEK | 91.571% |
| Duearity AB (publ) | 10.23 Million SEK | 205.125% |
| Dignitana AB (publ) | 13.07 Million SEK | 182.246% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 79.591% |
| Getinge AB (publ) | 5.4 Billion SEK | 100.199% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | 69.317% |
| Integrum AB (publ) | -10.47 Million SEK | -2.661% |
| Luxbright AB (publ) | -13.83 Million SEK | 22.251% |
| Mentice AB (publ) | -49.56 Million SEK | 78.3% |
| OssDsign AB (publ) | -162.78 Million SEK | 93.393% |
| Paxman AB (publ) | -11.41 Million SEK | 5.746% |
| Promimic AB (publ) | -50.32 Million SEK | 78.627% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 156.399% |
| SciBase Holding AB (publ) | -27.32 Million SEK | 60.638% |
| ScandiDos AB (publ) | -1.53 Million SEK | -602.504% |
| Sectra AB (publ) | -772.85 Million SEK | 98.608% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 95.259% |
| Senzime AB (publ) | -139.54 Million SEK | 92.292% |
| SpectraCure AB (publ) | -50.23 Million SEK | 78.59% |
| Stille AB | -178.5 Million SEK | 93.975% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 100.876% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 94.989% |